3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
153
Carcinoma, Non-Small-Cell Lung
94
Neoplasms
57
Breast Neoplasms
50
Urinary Bladder Neoplasms
47
Neoplasm Metastasis
43
Lung Neoplasms
41
Ovarian Neoplasms
36
Cholangiocarcinoma
31
Lymphoma
20
Sarcoma
19
Gallbladder Neoplasms
19
Fallopian Tube Neoplasms
19
Lymphoma, Large B-Cell, Diffuse
18
Biliary Tract Neoplasms
18
Recurrence
15
Lymphoma, Non-Hodgkin
15
Adenocarcinoma
14
Hodgkin Disease
13
Carcinoma, Transitional Cell
13
Bile Duct Neoplasms
13
Carcinoma
12
Colorectal Neoplasms
10
Head and Neck Neoplasms
8
Carcinoma, Renal Cell
8
Urethral Neoplasms
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Carcinoma, Ovarian Epithelial
7
Adenocarcinoma of Lung
7
Uterine Cervical Neoplasms
6
Interventions
Lenalidomide
3
Bortezomib
3
Dexamethasone
2
vandetanib
1
umbralisib
1
ublituximab
1
marizomib
1
durvalumab
1
carotuximab
1
avelumab
1
Zoledronic Acid
1
Vitamin D
1
Transplantation, Autologous
1
Tamoxifen
1
Standard of Care
1
Practice Guidelines as Topic
1
Palliative Care
1
Oxaliplatin
1
Melphalan
1
Leucovorin
1
Irinotecan
1
Granulocyte Colony-Stimulating Factor
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Filgrastim
1
Cyclophosphamide
1
Cisplatin
1
Carboplatin
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Disease Progression
×
Gemcitabine
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts